Abbkine’s Agarose Conjugated Anti-HA Tag Mouse Monoclonal Antibody (4F6) (ABT2043): A Precision Tool for Reliable HA-Tag Immunoprecipitation

HA (Hemagglutinin) tags remain a cornerstone of recombinant protein research, enabling selective isolation and purification of tagged proteins via immunoprecipitation (IP)—a technique critical for studying protein-protein interactions, post-translational modifications, and subcellular localization. Yet IP workflows targeting HA tags often face unresolved challenges: inconsistent antibody-agarose conjugation efficiency, high non-specific binding to endogenous proteins, limited compatibility across bacterial and mammalian expression systems, and loss of target protein during washing or elution steps. These pain points compromise data reproducibility and increase experimental costs, particularly for labs scaling across multiple model systems. Abbkine’s Agarose Conjugated Anti-HA Tag Mouse Monoclonal Antibody (4F6) (Catalog No.: ABT2043) addresses these critical gaps, merging optimized agarose conjugation, monoclonal specificity, and cross-species reactivity to set a new standard for HA tag IP assays.

The technical superiority of ABT2043 stems from its intentional integration of three core components: the 4F6 monoclonal antibody clone, high-quality agarose matrix, and rigorously validated conjugation chemistry. Unlike polyclonal anti-HA antibodies that recognize multiple epitopes (increasing off-target binding risk), the 4F6 clone binds exclusively to the conserved HA tag epitope (YPYDVPDYA), ensuring minimal cross-reactivity with endogenous proteins in mammalian (human, mouse, rat) or bacterial (E. coli, Bacillus subtilis) lysates. The agarose conjugation— a key differentiator—eliminates the need for researchers to separately conjugate antibody to matrix, a time-consuming step prone to variability in coupling efficiency. Abbkine’s proprietary conjugation process ensures uniform antibody loading (≥2 mg antibody per ml agarose) and stable binding, preventing antibody leaching during IP washes and preserving target protein integrity. For researchers transitioning between bacterial expression (for high-yield protein production) and mammalian systems (for functional studies), this cross-species compatibility eliminates the need for multiple IP antibodies, streamlining workflows and reducing experimental variability.

A defining industry trend shaping HA tag IP reagent development is the growing demand for “plug-and-play” solutions that balance specificity, scalability, and compatibility with high-throughput workflows. Traditional IP antibodies often require extensive optimization of conjugation conditions, antibody-to-matrix ratios, and wash protocols—barriers that slow down research and introduce human error. ABT2043 aligns with this trend by delivering a pre-conjugated, ready-to-use reagent that requires minimal protocol adjustment. Industry data indicates that pre-conjugated IP antibodies have seen a 42% growth in adoption over the past four years, driven by academic labs prioritizing reproducibility and biotech firms scaling up protein purification for drug discovery. Additionally, the shift toward multi-omics research—where IP is paired with mass spectrometry (MS) or Western Blot (WB) for downstream analysis—demands IP reagents with low background noise; ABT2043’s monoclonal specificity ensures that eluted samples are enriched for HA-tagged proteins, reducing MS false positives and enhancing WB signal clarity.

For researchers seeking to maximize ABT2043’s performance in IP assays, application-specific optimization strategies leverage the reagent’s unique properties while addressing common IP pitfalls. For bacterial lysates (high in contaminating proteins and nucleic acids), pre-clear samples with non-specific agarose beads for 30 minutes at 4°C to reduce non-specific binding; use 50–100 μl of ABT2043 agarose slurry per 1 mg of total protein, and incubate with gentle rotation overnight at 4°C to ensure complete target capture. For mammalian cell lysates (where protein-protein interactions are often labile), reduce incubation time to 4–6 hours at 4°C to minimize complex dissociation, and use a mild lysis buffer (e.g., RIPA with 1 mM PMSF and protease inhibitor cocktail) to preserve native protein structures. A critical technical insight: wash the agarose beads 4× with lysis buffer containing 150 mM NaCl (avoiding high-salt buffers >500 mM, which can disrupt antibody-HA tag binding) and elute with 100 μl of HA peptide (0.5 mg/ml) for 30 minutes at room temperature—this balances elution efficiency and target protein stability, outperforming harsh acid elution that denatures proteins.

Beyond technical performance, ABT2043’s value proposition reflects Abbkine’s commitment to delivering specialized reagents that meet the needs of both academic and industrial researchers. Priced at $279 for 1 ml of agarose-conjugated antibody, it offers a cost-effective alternative to premium competitors (which often exceed $350 for the same volume) while maintaining rigorous quality control: each batch is tested for conjugation efficiency, target binding capacity (≥10 μg HA-tagged protein per ml slurry), and cross-reactivity (no binding to non-HA-tagged proteins). The 1 ml format is scalable—suitable for small-scale validation experiments (using 10–20 μl slurry) or large-scale purifications (up to 10 mg total protein per ml slurry)—making it versatile for diverse research needs. Unlike generic agarose-conjugated antibodies that lack clone-specific validation, ABT2043’s 4F6 clone is optimized exclusively for IP, ensuring that researchers receive a reagent tailored to the demands of HA tag isolation rather than a multi-purpose tool with compromised performance.

As HA tag-based research continues to expand into functional proteomics and drug discovery, the need for reliable, specific, and scalable IP reagents becomes increasingly critical. Abbkine’s Agarose Conjugated Anti-HA Tag Mouse Monoclonal Antibody (4F6) (ABT2043) addresses this need by combining monoclonal specificity, pre-conjugated convenience, cross-species compatibility, and cost-effectiveness—attributes that make it an indispensable tool for researchers across disciplines. Whether isolating HA-tagged proteins from bacterial cultures, purifying protein complexes from mammalian cells, or scaling up IP for downstream MS analysis, ABT2043 delivers the reproducibility and efficiency required for high-impact research. To explore detailed technical specifications, access IP protocol templates, and procure the reagent, visit the official product page: https://www.abbkine.com/?s_type=productsearch&s=ABT2043. In an era where experimental rigor and workflow efficiency are paramount, ABT2043 redefines what a specialized HA tag IP antibody should be—targeted, reliable, and designed to accelerate scientific discovery.